Boehringer Further Buoys IPF Portfolio With Bridge's Autotaxin Inhibitor

Pre-IPO Bridge Biotherapeutics inks major idiopathic pulmonary fibrosis license agreement with Boehringer Ingelheim, marking the biggest single product licensing out deal by a South Korean biotech. The move is poised to further bolster the German firm's leading position in the field and reflects global pharma's increasing interest in IPF.

Neon Light Sign Lungs Icon
Bridge Deal Cements Boehringer's Leadership In IPF • Source: Shutterstock

Bridge Biotherapeutics Inc. has reached a global licensing out and collaboration agreement with Boehringer Ingelheim GmbH for the South Korean biotech’s early clinical stage molecule BBT-877 for the treatment of fibrosing interstitial lung diseases including idiopathic pulmonary fibrosis (IPF), in a deal worth as much as €1.145bn ($1.29bn).

BBT-877, a potent small molecule inhibitor of autotaxin (ATX), is undergoing a Phase I trial in the US and is...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from South Korea

More from Focus On Asia